Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
Murray J, Rosenthal R, Somerville L, Blake K, House K, Baitinger L, VanderMeer A, Dorinsky P. Murray J, et al. Among authors: house k. Ann Allergy Asthma Immunol. 2004 Oct;93(4):351-9. doi: 10.1016/S1081-1206(10)61394-4. Ann Allergy Asthma Immunol. 2004. PMID: 15521371 Clinical Trial.
Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products.
Daley-Yates PT, Parkins DA, Thomas MJ, Gillett B, House KW, Ortega HG. Daley-Yates PT, et al. Clin Ther. 2009 Feb;31(2):370-85. doi: 10.1016/j.clinthera.2009.02.007. Clin Ther. 2009. PMID: 19302910
Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
Nathan RA, Rooklin A, Schoaf L, Scott C, Ellsworth A, House K, Dorinsky P. Nathan RA, et al. Among authors: house k. Clin Ther. 2006 Jan;28(1):73-85. doi: 10.1016/j.clinthera.2006.01.008. Clin Ther. 2006. PMID: 16490581 Clinical Trial.
Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM. Cowie RL, et al. Among authors: house kw. Clin Ther. 2007 Jul;29(7):1390-402. doi: 10.1016/j.clinthera.2007.07.021. Clin Ther. 2007. PMID: 17825690 Clinical Trial.
90 results